Supplementary Figure 1. Enhanced anti-tumor immune responses in Rnf5
-/-mice. A, Growth of B16F10, YUMM1.9, YUMM1.3, and YUMM1.3-shRnf5 melanoma cells in WT and Rnf5 -/-mice (n = 5). B, Survival of WT and Rnf5 -/-mice bearing YUMM1.5 melanoma (WT, n = 9; Rnf5 -/-, n = 10). Loss of survival was defined as death or when tumor diameter reached or exceeded 2cm in any dimension or the tumor volume reached 2 mm 3 . C, Quantification of tumor-infiltrating (CD44 hi ) CD4 + and CD8 + T cells on day 16 after injection of 10 6 YUMM1.5 cells into WT and Rnf5 -/-mice (n = 5). D, Representative flow cytometry plots of cytokine production by tumor-infiltrating CD4 + and CD8 + T cells. E, MFI of MHC class II, CD80, and CD86 in tumor-infiltrating macrophages on day 24 after injection of YUMM1.5 cells (n = 5). F, MFI of PD-1, LAG-3, and TIM-3 in tumor-infiltrating (CD44 hi ) CD4 + and CD8 + T cells at day 24 after injection of YUMM1.5 cells (n = 5). G, MFI of PD-L1 in tumor-infiltrating DCs or macrophages on day 24 after injection of YUMM1.5 cells (n = 5). H, Frequency of CD45.1 + CD8 + OT-I T cells from TdLN or ndLN from WT or Rnf5 -/-mice (WT, n = 6; Rnf5 −/− , n = 5). I, Representative FACS profiles showing dilution of CFSE staining in CD45.1 + CD8 + WT OT-1 T cells from TdLNs and ndLNs. J, Tumor growth after injection of YUMM1.5 cells into WT or Rnf5 -/-mice treated with control IgG or anti-PD-1 antibody (IgG, n = 9; anti-PD-1, n = 8). K, Tumor growth after injection of YUMM1.5 cells into WT or Rnf5 -/-mice treated with control IgG or anti-CTLA-4 blocking antibody (n = 9). Data are representative of three independent experiments (A, D-G), two independent experiments (C, H-J) and one experiment (B, K). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-way ANOVA with Sidak's or Bonferroni's correction (A, J and K) or or log-rank test (B). Individual mice were analyzed by two-tailed t-test or Mann-Whitney U test (C, E-H).
Supplementary Figure 2. Enhanced anti-tumor immunoregulatory gene expression in Rnf5
-/-mice. A, NanoString analysis of PanCancer Immune Profiling genes in YUMM1.5 melanoma tumors from WT and Rnf5 -/-mice. The heat map shows 403 genes with >1.2-fold difference (P < 0.05) in expression between the two strains (n = 5). B, Ingenuity pathway analysis of upstream regulators and effectors in tumors from Rnf5 -/-mice compared with WT mice. C, qPCR validation of differentially expressed genes identified by gene expression profiling of tumors from WT and Rnf5 -/-mice (n = 5). D, CCL5 levels in the serum of WT or Rnf5 -/-mice 10 days after tumor inoculation (n = 5). E, qRT-PCR analysis of pathogen receptor mRNA levels in IECs from naïve WT or Rnf5 −/− mice (n=4). Data are representative of three independent experiments (C) and two independent experiments (D, E). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann-Whitney U test.
Supplementary Figure 3. Marked difference in microbial community structure between Rnf5
-/-and WT mice. A, MFI of MHC class II on tumor-infiltrating DCs (CD45 + CD11c + ) in tumor-infiltrating effector (CD44 hi ) CD8 + T cells from WT or Rnf5 -/-mice housed alone or together (mixed) for 4 weeks prior to YUMM1.5 inoculation. Cells were analyzed on day 24 after inoculation (n = 10). B, Correlation heat map of the relative abundance of the 38 taxa. The color and size of the circles indicate Spearman's correlation for the relative abundance of taxa and the significance of the correlation, respectively (n = 60). C, Boxplot of the relative abundance of the 11 taxa enriched in Rnf5 -/-mice microbiota that are negatively correlated with tumor size (n = 30). D, Boxplot of the relative abundance of the 27 taxa enriched in WT mice microbiota that are positively correlated with tumor size (n = 30). E, Fecal samples were weighed and DNA were extracted. Quantification of different bacterial copy number in WT and Rnf5 -/-mice were performed on day 0 and day 24 (n = 8). Data are representative of two independent experiments (A, E). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by one-way ANOVA with Tukey's correction. Supplementary Figure 4 . B. rodentium induced ER stress signature and activated components of the TLR signaling pathway. A, SW1 tumor growth in ASF-bearing C3H/HeN mice undergoing oral gavage with or without bacterial cocktail prior to tumor inoculation (ASF, n = 15; ASF + bacterial cocktail, n = 14). B, Quantification of B. rodentium abundance on day 24 after tumor injection in WT or Rnf5 −/− mice treated with control IgG or anti-CTLA-4 blocking antibody on days 7, 10, 13, and 16 after injection of YUMM1.5 tumor cells (n = 9). C, qRT-PCR analysis of the indicated ER stress-related and TLR signaling pathway mRNAs in MODE-K cells left untreated (control) or incubated with B. rodentium (n = 6). Data are representative of three independent experiments (C) and one experiment (A). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann-Whitney U test (C), one-way ANOVA with Tukey's correction for multiple comparisons (B) or two-way ANOVA (A).
Supplementary Figure 5. Altered intrinsic inflammation in Rnf5
-/-mice. A, Serum cytokines in naïve WT or Rnf5 −/− mice (n=6). B, H&E-stained small intestine Swiss roll sections in YUMM1.5 tumor-bearing WT mice or Rnf5 -/-mice (upper panels). Villi length (red bracket) and crypt depth (black bracket) were labeled in the lower panel (scale bar 100μm). C, Villi lengths and crypt depth in YUMM1.5 tumor-bearing WT and Rnf5 −/− mice co-housed for 4 weeks prior to tumor inoculation (n = 32). D, qRT-PCR analysis of CCL5 mRNA levels in MODE-K-shCon and MODE-K-shRnf5 cells (n = 3). E, MFI of MHC class I and II on bone marrow-derived dendritic cells (BMDCs) incubated with media alone (no stimulation), conditioned media (CM) from shControl or shRNF5 MODE-K cells (n = 4). F, Percentage of total DCs and pDCs in Peyer's patches isolated from naïve WT or Rnf5 −/− mice (n = 6). G, H, Average of cytokine and chemokine secretion by FACS-sorted CD45 + NK1.1 − CD19 − Thy1.2 − CD11c + DCs isolated from Peyer's patches from naïve (WT) and Rnf5 -/-mice (pooled from n = 10/group). Cells were cultured with or without ligands for TLR1/2 (Pam3CSK4, 300 ng/ml), TLR4 (LPS, 1 µg/ml), TLR7 (R848, 10 µg/ml), and TLR9 (ODN1826, 5 µM) for 18 h, and the supernatants were removed for quantification of cytokines (G) and chemokines (H). I, 10 days after tumor injection, DCs from PP and MLN were isolated and pooled per group (n=10 mice/group 
n=10). Data are representative of three independent experiments (D, E) and two independent experiments (A-C, F-J).
Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann-Whitney U test (A, D, F, I and J) or one-way ANOVA with Tukey's correction for multiple comparisons (C and E).
Supplementary Figure 6. Altered UPR in Rnf5
-/-mice induce concerted changes in the gut microbiome and immune response. A, Western blot analysis of the indicated proteins in lysates of YUMM1.7 melanoma cells treated with 3μM BFA for indicated time. Parental, homozygote Rnf5 -/-(two independent clones. #3 and #4), and a heterozygote Rnf5 +/-clone (#44) are shown. B, qRT-PCR analysis of sXBP1 mRNA in the cells shown in (a) treated with 3μM BFA for indicated time. C, qRT-PCR analysis of mRNA levels of sXBP1, ERdj4, and indicated triglyceride-related genes in MODE-K cells expressing control or RNF5-specific shRNA. D, RT-PCR analysis of indicated ER stress-related mRNAs in bone marrow-derived macrophages (BMDMs) from WT and Rnf5 −/− mice after treatment in vitro with or without 1μM thapsigargin (TG) for indicated times (n = 4). E, Western blot analysis of the indicated proteins in lysates of BMM treated with tumor DNA for indicated times (n = 3). F, As in panel E, except that BMDC were treated with DMXAA for indicated times (n = 3). Data are representative of three independent experiments (B, C, D) and two independent experiments (A, E, F). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 by two-tailed t-test or Mann-Whitney U test (C-D) or one-way ANOVA with Tukey's correction for multiple comparisons (B).
Supplementary Figure 7.
Reduced expression of UPR components in murine melanoma responders to anti-CTLA4 treatment. A, RT-PCR analysis of indicated UPR-related mRNAs of B2905 melanomas collected from the mice treated with isotype or anti-CTLA4 antibodies (IgG, Non-Responder anti-CTLA4, n = 5; Responder anti-CTLA4, n = 4). B, Tumor growth after s.c. injection of YUMM1.7-shCon and YUMM1.7-shXBP1 cells into C57BL/6 mice treated with control IgG or anti-PD-1 antibody on days 7, 10, 13, and 16 after tumor inoculation (n = 8). Data are representative of two independent experiments (B) and one experiment (A). Graphs show the mean ± s.e.m. *P < 0.05, **P < 0.005 by one-way ANOVA (A) or twoway ANOVA (B) with Tukey's correction for multiple comparisons. Figure 1C and 1F Figure 1D , 1E, 3F and Supplementary Figure 1G , as described before 1 . C. Gating strategy of the tumor infiltrating macrophages (CD45 + F4/80 + CD11b + ) presented on Supplementary Figure 1E . D, Gating strategy of sorted DCs (CD45 + CD11C + NK1.1 -CD19 -Thy1.2 -) from PPs presented on Figure 5G , and Supplementary Figure 5G , 5H and 5I. E, Gating strategy of the tumor infiltrating DCs, mDCs, pDCs and CD8α + DCs from PPs presented on Figure 5F and Supplementary Figure 5F 1000029; 1000209; 1000378; 1000903; 1002068; 1008650; 1003766; 1003967; 1006687; 1007582; 1003350; 1009582; 1001283; 1002382; 1004060; 1001070; 1002919; 1002962; 1003887; 1005818; 1001077; 1004334; 1005821; 1004681; 1007313; 1006597; 1005007; 1005599; 1004385; 1004391; 1006523; 1004899; 1003569; 1004779; 1003791; 1001860; 1002089; 1002191; 1010826; 1001302; 1003570; 1008811; 1001053; 1003705; 1003055; 1006356; 1003794; 1000985; 1001164; 1000176; 1002675; 1006311; 1001089; 1003727; 1002522; 1007531; 1003617; 1001932; 1003358; 1000856; 1005846; 1008928; 1001631; 1001208; 1007092; 1001538; 1008605; 1008178; 1000916 
